CDXS (Codexis) Debt-to-Asset : 0.40 (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Codexis Debt-to-Asset?

Codexis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $2.83 Mil. Codexis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $57.07 Mil. Codexis's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $149.01 Mil. Codexis's debt to asset for the quarter that ended in Dec. 2024 was 0.40.

Codexis Debt-to-Asset Historical Data

The historical data trend for Codexis's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Debt-to-Asset Chart

Codexis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.11

0.19

0.17

0.12

0.40

Codexis Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.12	0.29	0.32	0.28	0.40

Competitive Comparison of Codexis's Debt-to-Asset

For the Biotechnology subindustry, Codexis's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Codexis's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Codexis's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Codexis Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Codexis's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.827	+	57.068)	/	149.011
	=	0.40

Codexis's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.827	+	57.068)	/	149.011
	=	0.40

Codexis (NAS:CDXS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Codexis Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Codexis's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Codexis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (NAS:CDXS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

0I0X:UK 4QK:Germany

Address

200 Penobscot Drive, Redwood City, CA, USA, 94063

Website

https://www.codexis.com

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Executives

Byron L Dorgan	director	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Norrett	officer: Chief Operating Officer	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Margaret Nell Fitzgerald	officer: See Remarks	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Sriram Ryali	officer: Chief Financial Officer	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Stephen George Dilly	director, officer: See Remarks	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
John J Nicols	director, officer: President and CEO	ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
H Stewart Parker	director
Rahul Singhvi	director	246 HOLLY DRIVE, CHALFONT PA 18914
Dennis P Wolf	director	1101 EAST MEADOW DR, PALO ALTO CA 94303
Patrick Y Yang	director	C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Bernard J Kelley	director
Esther Martinborough	director	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jennifer Aaker	director	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Alison Moore	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas R Baruch	director	1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129